The expanding Illumina oncology portfolio of next-generation sequencing (NGS) and microarray technologies is revolutionizing cancer genomics research. Our simple, sample-to-data solutions deliver highly accurate, reproducible results for the discovery and analysis of cancer variants. Perform whole-genome, tumor/normal, RNA, and targeted sequencing in record time. Complete epigenetic analysis, germline risk assessment, and cytogenetics studies with ease. Through cancer community partnerships, we are enhancing our technologies with one goal in mind: To develop transformative solutions that deliver relevant cancer genomics information into the hands of translational and clinical researchers.
Germline mutations that predispose individuals to cancer can be detected through various approaches, ranging from genome-wide association studies (GWAS) to whole-genome and targeted gene sequencing. Learn more about detecting germline mutations »
Tumor/normal sequencing studies are critical to distinguish between unique somatic mutations accrued by a tumor and germline mutations also present in the surrounding normal tissue. Illumina sequencers offer the speed and accuracy to detect these mutations. Learn more about detecting somatic mutations »
Analyzing the entire cancer transcriptome or targeted transcripts with RNA-Seq allows researchers to detect significant expression changes, and to potentially identify genes associated with tumor progression. Learn more about RNA-Seq detection of gene expression & transcriptome changes »
Analysis of epigenetic changes in cancer cells, such as aberrant methylation and altered transcription factor binding, can provide key insights into tumorigenesis. Learn more about Illumina's NGS and array methods for detecting epigenetic changes »
Genomic instability and chromosomal rearrangements are frequent features of cancer. Illumina offers both array- and sequencing-based approaches to identify gross chromosomal changes. Learn more about identifying chromosomal abnormalities »
NGS methods enable researchers to perform whole-genome studies, targeted gene profiling, gene expression, and epigenetic studies on polyclonal tumor samples at a pace unheard of a few years ago. Learn more about cancer sequencing methods »
The analysis of next-generation sequencing data from cancer samples can be challenging. Illumina offers a number of software options and analysis tools to simplify this process. Learn more about cancer data analysis »
Dr. Daber uses TruSeq Custom Amplicon to identify genomic changes in tumor specimens.
Access PDF »
Identify true somatic variants even in low purity samples with this data analysis workflow.
Access PDF »
A first-of-its kind program transforming our ability to understand, classify, and treat 12 types of cancer.
Explore TCGA »
NGS-based cancer studies offer a deeper understanding of tumor biology.
Access PDF »
The MiSeq sequencer enables comprehensive profiling of tumor samples. Interrogate a wider range of mutations than is possible with traditional technologies.
View System »
For Research Use Only.
Quote attributed to Seishi Ogawa, Ph.D.:
"Cancer is caused by genetic mutations. To fully understand their functional consequences it is essential to view the complete spectrum of genetic alterations both at the DNA and RNA level, as well as copy number and methylation changes. Our research aims to understand the genetic basis of various human cancers using revolutionized sequencing technologies."